Plain-English translation of NCT06067347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying patients with T-cell and NK-cell lymphomas — uncommon blood cancers affecting specific immune cells. By collecting medical records, tumor samples, and quality-of-life information from patients around the world over four years, the study will use artificial intelligence and genetic testing to predict which treatments are most likely to work for each patient, even if they haven't tried those treatments yet.
T-cell and NK-cell lymphomas are rare and difficult to treat, and doctors don't yet have good ways to predict which patients will respond to different treatments. This study aims to use advanced technology and machine learning to help personalize treatment decisions and improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
You will be followed at your cancer center for up to four years as you receive your regular cancer care. During this time, researchers will collect your medical information, pathology reports, imaging results, and quality-of-life surveys at routine visits. You may also have blood drawn or provide saliva samples for genetic testing. All your information will be de-identified (your name removed) and securely shared with researchers at other participating institutions to train artificial intelligence models that predict treatment outcomes.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States